Preparation method of brivaracetam

A technology of temperature control and solvent, which is applied in the field of preparation of buvaracetam, can solve the problems of unfavorable production efficiency, long time-consuming, high production cost, etc., and achieve the advantages of less time-consuming reaction steps, improved production efficiency and production cost Effect

Inactive Publication Date: 2018-03-13
LIVZON NEW NORTH RIVER PHARMA
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] CN101263113B discloses the preparation of buvaracetam by the method shown in route 3, and this method reaction route is longer, and operation is more loaded down with trivial details; And needs to pass through column chromatography purification twice, and total yield is lower, and production cost is higher
[0014] Compared with the synthetic method disclosed in patent CN1208319C, document J.Med.Chem., 2004,47(3)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of brivaracetam
  • Preparation method of brivaracetam
  • Preparation method of brivaracetam

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Hydrogenolysis: Synthesis of Compound 3

[0078]

[0079] In a 1000ml hydrogenation kettle, 450ml of ethyl acetate, 300g (2.11mol) of compound 4, and 10g of 5wt% Pd / C were sequentially added. After the mixture is stirred evenly, seal the hydrogenation tank and use N 2 and H 2 Replace the air in the system. Control the temperature at 25-30°C, H 2 The pressure was controlled at 0.2-0.3MPa, and the mixture system was stirred for 2 hours. Then terminate the reaction, using N in turn 2 and air displacement system H 2 . After the mixture was filtered to separate Pd / C, the solution was distilled off the solvent under reduced pressure at 45-50°C to obtain the crude compound 3 without further treatment, which can be directly put into the subsequent reaction). The reaction time is 2.5 hours.

Embodiment 2

[0081] Hydrogenolysis: Synthesis of Compound 3

[0082]

[0083] In a 1000 ml hydrogenation kettle, 400 ml of isopropyl acetate, 240 g (1.68 mol) of compound 4, and 8 g of 5% Pd / C were successively added. After the mixture is stirred evenly, seal the hydrogenation tank and use N 2 and H 2 Replace the air in the system. Control the temperature at 20-25°C, H 2 The pressure is controlled at 0.15-0.25 MPa, and the mixture system is reacted for 2 hours under stirring condition. Then terminate the reaction, using N in turn 2 and air replacement system H 2 . After the mixture was filtered to separate Pd / C, the solution was distilled off under reduced pressure at 55-60°C to remove the solvent to obtain a crude compound 3 (which can be directly put into subsequent reactions without further treatment). The reaction time was 2.5 hours.

Embodiment 3

[0085] Reductive amination / lactamization: Synthesis of compound 1 (including 1-a and 1-b)

[0086]

[0087] (1) Amination: In a 1000ml three-necked round-bottomed flask, under a nitrogen atmosphere, 38.8g of compound 2 (0.38mol) was dissolved in 500ml of toluene, the temperature was controlled to 15-20°C, and 49.8g of compound 3 ( 0.34mol) in toluene (150ml) solution. After the dropwise addition was complete, the stirring reaction was continued at this temperature for 3.5 hours.

[0088] (2) Reduction: After the precipitate is completely precipitated, add 52ml of 4mol / L NaOH aqueous solution dropwise to the suspension, then add 8.5g (0.22mol) of sodium borohydride (85ml) solution dropwise, and after about 2.5 hours, add 42ml dropwise The reaction solution was carefully quenched with acetic acid.

[0089] (3) Lactamization: After heating and reacting at 45-50° C. for 3.5 hours, naturally cool to room temperature.

[0090] (4) Post-processing and purification: Add 27.5ml o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a preparation method of brivaracetam, comprising the steps of (1) aminating, to be specific, dissolving compounds 2 and 3 in solvent 2, and stirring at controlled temperature of10-50 DEG C to allow reacting for 2-3 h, wherein the solvent 2 is one or more of methylbenzene, 1,2-dichloroethane, dichloromethane, trichloromethane and tetrahydrofuran; (2) reducing, to be specific, adding a reducing agent, and allowing reacting at controlled temperature of 10-50 DEG C for 1-4 h, wherein the reducing agent is one or more of sodium borohydride, potassium borohydride and sodium triacetoxyborohydride; (3) performing lactamization, to be specific, allowing reacting at controlled temperature of 20-100 DEG C for 2-5 h, wherein the steps (1) to (3) are performed in inert gas environment. The intermediate compounds of brivaracetam used herein are low in price, and the preparation method has mild reaction conditions and is suitable for industrial large-scale production.

Description

technical field [0001] The invention relates to the technical field of pharmacy, in particular to a preparation method of buvaracetam. Background technique [0002] Brivaracetam (Brivaracetam, CAS: 357336-20-0), trade name Briviact, chemical name (2S)-2-[(4R)-2-oxo-4-propyl-1-pyrrolidinyl]butyl Amide, the structural formula is shown in the following compound 1-a: [0003] [0004] Brivaracetam is a new type of antiepileptic drug developed by UCB, Belgium. It has been approved by the European Medicines Agency (EMA) on January 14, 2016 and the US Food and Drug Administration on February 18, 2016. Bureau (FDA) approved marketing. As the third-generation antiepileptic drug developed by the company, Brivaracetam is a structural derivative of Levetiracetam, which is also a highly selective and high-affinity central synaptic vesicle protein 2A ( SV2A) ligand. Compared with levetiracetam, the binding force of brivaracetam to SV2A is about 10 times that of levetiracetam, and i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D207/27
CPCC07D207/27
Inventor 姜桥杨通胜邓意黄从汉向双
Owner LIVZON NEW NORTH RIVER PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap